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How This Fits In 
Comorbidity is known to be a common problem in patients with heart failure, but previous 
studies have been based on a small number of comorbid conditions using mainly non-primary 
care data sources. The current study compared prevalence rates of comorbidity in those with 
and without chronic heart failure due to left ventricular systolic dysfunction (LVSD) using 
nationally representative primary care data from 314 general practices and 1,421,756 patients 
in Scotland. Compared with standardised controls, the LVSD group had elevated 
comorbidity, with 25/31 physical and 6/7 mental health conditions being significantly more 
common. Polypharmacy of 11 or more drugs was also more common in the LVSD group. 
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Abstract 
Background 
Comorbidity is common in heart failure, but previous prevalence estimates have been based 
on a limited number of conditions using mainly non-primary care data sources. 
Aim 
To compare prevalence rates of comorbidity and polypharmacy in those with and without 
chronic heart failure due to left ventricular systolic dysfunction (LVSD). 
Design 
Cross-sectional study 
Setting 
314 general practices and 1,421,756 patients in Scotland. 
Methods  
Data on the presence of LVSD, 31 other physical and seven mental health comorbidities and 
prescriptions were extracted. Comorbidity prevalence were compared in patients with and 
without LVSD, standardised by age, gender and deprivation 
Results 
17,285 people (1.2%) had a diagnosis of LVSD. Compared with standardised controls, the 
LVSD group had more comorbidity, with the biggest difference found for seven or more 
conditions (OR 4.10 95% CI 3.90-4.32). Twenty-five physical conditions and six mental 
health conditions were significantly more prevalent in those with LVSD relative to 
standardised controls. Polypharmacy was higher in the LVSD group compared with controls, 
with the biggest difference found for 11 or more repeat prescriptions (OR 4.81; 95% CI 4.60 
to 5.04). However, these differences in polypharmacy were attenuated after controlling for 
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the number of morbidities, indicating that much of the additional prescribing was accounted 
for by multimorbidity rather than LVSD per se. 
Conclusions 
Extreme comorbidity and polypharmacy is strikingly more common in patients with chronic 
heart failure due to LVSD. The efficient management of such complexity requires the 
integration of generalist and specialist expertise. 
 
Keywords: heart failure; multimorbidity; general practice; comorbidity 
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Introduction 
Chronic heart failure constitutes a major public health problem.1, 2 The prevalence of chronic 
heart failure is increasing.3,4 and despite improvements in mortality,5 approximately 50% of 
those diagnosed die within five years.6 Chronic heart failure also impacts on quality of life7 
and increases “treatment burden” 8, 9 and challenging self-care demands.10  
 
Patients with chronic disease often have multiple conditions11. More than half of all 
hospitalisations of heart failure patients are related to non-cardiovascular causes.12 
Comorbidity is common in heart failure,13,14,15  especially in older patients.16,17  
Comorbidities in heart failure increase mortality and resource utilisation18,19,.20and worsen 
self care.21  
 
However, much of this evidence on comorbidity in heart failure comes from studies of 
hospital discharge records, studies considering a relatively limited number of chronic 
conditions, or studies with relatively small sample sizes.22,23 Data from primary care - the 
location of most health care interactions with heart failure patients -is scarce. The aim of the 
present study was to examine the prevalence of convergent and divergent comorbidity in 
chronic heart failure using a large, nationally representative cross-sectional UK primary care 
dataset. Polypharmacy was also examined. 
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Methods 
We used data from the Primary Care Clinical Informatics Unit at the University of Aberdeen  
on 1,424,378 individuals, aged 18 years or older, who were alive and permanently registered 
with 314 general practices (31% of all practices in Scotland) on March 31, 2007 registered 
with a participating practice. These practices had recorded routine electronic clinical data as 
part of the Scottish Programme for Improving Clinical Effectiveness in Primary Care 
(SPICE-PC), which was a voluntary scheme run by the Scottish Government, and was a 
nationally representative sample in terms of patients age, gender, and socioeconomic status.24 
Socioeconomic status was measured using the Carstairs score (grouped into quintiles). The 
dataset provided information on age, gender, socioeconomic status and 39 long term 
conditions. In total 18,899 individuals were identified as having heart failure through having 
a  Read Code for heart failure recorded in their primary care electronic medical record 
(EMR). Heart failure due to left ventricular systolic dysfunction (LVSD) is one of a number 
of chronic conditions, whose accurate diagnosis and optimal management has been 
incentivised through the UK Quality and Outcomes Framework (QOF) pay-for-performance 
programme since 2004. We restricted analysis to 17,285 individuals who have been 
diagnosed heart failure due to LVSD who were identified using QOF indicator heart failure 
03.25 The control group were defined as the entire population of adults without LVSD.  
 
To control for differences between the two populations in age, gender and deprivation levels 
we adopted a similar approach to that undertaken in previous papers26 27  and generated 
standardised prevalence rates by age groups (18 to 24 years; 25 to 34; 35 to 44; 45 to 54; 55 
to 64; 65 to 74; 75 to 84 and 85 and over), gender and deprivation quintile using the direct 
method. These age-gender-deprivation standardised rates were then used to calculate odds 
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ratio (ORs) and 95% confidence intervals (95% CI) for those with LVSD compared to those 
without (controls) for the prevalence of 31 physical conditions. There were seven mental 
health conditions (depression, alcohol misuse, learning disability, anorexia/bulimia, ‘anxiety 
and other neurotic, stress-related and somatoform disorders’, ‘schizophrenia and related 
conditions’, and dementia).  For all statistical analyses, a p-value less than 0·05 was 
considered statistically significant. All analyses were performed in Stata version 13. The 
NHS Grampian Research Ethics Service approved the anonymous use of these data for 
research purpose.  
 
Results 
Demographics 
There were 17,285 (1.2% of the sample) patients with a code for LVSD (table 1). Men were 
over-represented in the LVSD group compared to (unadjusted) controls (53.5% vs. 49.1% for 
controls; p <0.001). Individuals with LVSD were on average older (mean age 72.3 years vs. 
47.6 years for controls; P <0.001). People with LVSD were marginally more likely to be 
living in the most deprived areas compared to unadjusted controls (LVSD most deprived 
quintile 20% vs controls 17.8%; p<0.001). Overall only 3.2% of individuals with heart failure 
had no other condition compared to 52.0% of unadjusted controls with no recorded condition 
(table 2)  
 
Comorbidity: LVSD compared with standardised controls 
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After standardising for age, sex and social deprivation (table 2) higher levels of comorbidity 
were evident in the LVSD group who were less likely to have none, one or two conditions but 
more likely to have three conditions (LVSD 17.5% vs. controls 4.0%; OR 4.10 95% CI 3.90-
4.32). The biggest difference found was for seven or more conditions (LVSD 13.9% vs. 
controls 1.1%; OR 4.10 95% CI 3.90-4.32). A similar, though even more striking, pattern was 
found when restricting analysis to physical health comorbidities (table 2) with a five-fold 
difference between LVSD and controls being found in those with seven or more conditions 
(OR 5.10 (95% CI 4.79 to 5.43)).  
 
Mental comorbidity was also more common in those with LVSD who were less likely to have 
no mental condition (LVSD 71.9% vs. controls 84.9%; OR 0.67 95% CI 0.65-0.70) and were 
more likely to have one, two or three or more mental health conditions ranging from OR 1.41 
95% CI 1.36 to 1.47 (LVSD 20.3% vs. controls 11.5%) for one condition to OR 1.39 95% CI 
1.19 to 1.61 (LVSD 20.3% vs. controls 11.5%) for three or more mental health conditions 
(table 2). 
 
Physical health individual conditions: LVSD compared with controls 
For the LVSD group, 25 (including all 6 concordant conditions) out of 31 physical conditions 
were significantly more prevalent relative to controls (figure 1). The largest differences after 
standardisation for age, sex and deprivation were for ‘concordant’ conditions; coronary heart 
disease (CHD) (OR 7.98, 95% CI 7.72-8.25) atrial fibrillation (OR 6.84, 95% CI 6.57-7.12) 
and chronic kidney disease (CKD) (OR 3.81, 95% CI 3.18-3.46). However, large differences 
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were also found for non-cardiometabolic conditions such as chronic pain (OR 3.01, 95% CI 
2.90-3.12) and COPD (OR 2.51, 95% CI 2.38-2.65). 
 
Mental health conditions: LVSD compared with controls 
Table 3 highlights that those with LVSD had significantly higher prevalence for six of the 
mental health conditions with no difference found for anorexia/bulimia. The biggest 
difference after standardisation for age, sex and deprivation was for anxiety and stress related 
conditions (LVSD 11.0% vs. controls 3.8%; OR 1.83, 95% CI 1.73-1.94), followed by 
alcohol problems (LVSD 4.9% vs. controls 3.0%; OR 1.73, 95% CI 1.62-1.86). The highest 
prevalence for a mental health condition was found for depression with prevalence 16.3% for 
those with LVSD compared to 10.1% of controls (OR 1.48 95% CI1.41-1.54.)  
 
Polypharmacy: LVSD compared with controls 
Polypharmacy (defined as 5 or more repeat drugs) was substantially higher in the LVSD 
group compared with controls even after standardisation for age, gender, and deprivation 
(table 4). However, these differences were substantially attenuated after additional 
standardisation to account for the number of morbidities, indicating that much of the 
additional prescribing was accounted for by comorbidity rather than LVSD per se (see figure 
2).  
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Discussion 
Summary 
This analysis has found that comorbidity of physical and mental health chronic conditions are 
more common in those with LVSD even after standardisation for age, sex and deprivation.  
 
Strengths and limitations 
Strengths of our study were that we used a large nationally representative primary care 
database.  We used LVSD as our measure for heart failure prevalence. The percentage of 
heart failure due to LVSD of 91.5% is similar to that found for all Scottish practices recorded 
in the QOF in the same year of 88.7%.28  A limitation is that no data was available on the 
number of those with LVSD who had been identified using an echocardiogram. However, 
heart failure is routinely investigated in NHS Scotland using an echocardiogram. We 
included 39 morbidities in addition to LVSD, substantially more than most other studies of 
comorbidity and LVSD.  However, the study was cross sectional and there was no data on 
outcomes. 
 
Comparison with existing literature 
Direct comparison of the current study with existing literature is difficult as most previous 
studies have focused on the elderly, included a smaller number of conditions, not had a 
control group, and not been primary care based. However, the markedly higher prevalence of 
comorbidity in heart failure is consistent across studies, as is the finding of high levels of 
‘concordant’ conditions such as CHD, CKD, and atrial fibrillation. The high level of chronic 
pain in the LVSD group in the present study appears to be a novel finding, which is worthy of 
further investigation.  
 
 
11 
 
Its is possible of course that the higher level of comorbidities in LVSD in part reflects higher 
rates of diagnosis, since these patients would be invited for annual review under QOF. 
Similarly, the higher levels of polypharmacy could also relate to this and the fact that QOF 
recommends putting LVSD patients on at least two drugs (ACEi/ARB and b-blocker).  
 
Implications for research and practice 
Recent heart failure clinical guidelines acknowledge the issue of comorbidity but do not 
address the specific challenges.29 30  The evidence underpinning recommendations in LVSD 
guidelines is largely created from randomised controlled trials which exclude older and more 
comorbid individuals.31 32 Many evidence gaps remain in the clinical management of 
comorbidity in LVSD.  For example, the safety and efficacy of many treatments for 
comorbidities in the context of LVSD as well as the drugs recommended for LVSD remain 
uncertain.   
 
In conclusion, the current study has provided a comprehensive picture of current patterns of 
comorbidity in primary care in those with chronic heart failure due to LVSD. Comorbidity is 
clearly the norm in LVSD. Clinical guidelines and health care services need to put greater 
emphasis on management of such complexity in LVSD, which will require the application 
and integration of generalist and specialist expertise.  
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Table 1 Age, gender and deprivation status, LVSD versus controls 
Variable LVSD 
N=17,825 (1.2% of all 
patients) 
No. (%) 
Controls 
N=1,404,471 (98.8%) of all 
patients 
No. (%) 
Men 9,242 (53.5%) 88,967 (49.1%) 
Mean Age (sd) 72.3 (13.1) 47.6 (18.1) 
   Age Group 
 
18-24 
25-34 
35-44 
45-54 
55-64 
65-74 
75-84 
    85 and over 
 
 
39 (0.2) 
126 (0.7) 
396 (2.3) 
1,129 (6.5) 
2,573 (14.9) 
4,654 (26.9) 
5,902 (31.2) 
2,966 (17.3) 
 
 
151,650 (10.8) 
229,266 (16.3) 
278,567 (19.8) 
252,579 (18.0) 
216,542 (15.4) 
150,120 (10.7) 
93,009 (6.6) 
32,738 (2.3) 
Deprivation quintile 
Least Deprived 
2 
3 
4 
Most deprived 
 
3,526 (20.4) 
3,531 (20.4) 
3,644 (21.1) 
3,127 (18.1) 
3,457 (20.0) 
 
268,122 (19.1) 
300,086 (21.4) 
317,963 (22.6) 
267,710 (19.1) 
250,590 (17.8) 
 
 
14 
 
Table 2 LVSD status and number of morbidities 
 
 
LVSD N (%) 
N=17,285 
Controls (%) 
N=1,404,471 
Age, gender and deprivation 
standardised Odds Ratio (95% CI) 
a 
Total number of morbidities 
None 
One 
Two 
Three 
Four 
Five 
Six  
Seven or more 
  
558 (3.2) 
1.831 (10.6) 
2,555 (14.8) 
3,023 (17.5) 
2,835 (16.4) 
2,375 (13.7) 
1,707 (9.9) 
2,401 (13.9) 
 
729,975(52.0) 
300,219 (21.4) 
160,823 (11.5) 
94,847 (6.8) 
55,726 (4.0) 
31,401 (2.2) 
16,748 (1.2) 
14,732 (1.1) 
 
0.90 (0.10 to 0.80) 
0.47  (0.45 to 0.50) 
0.77 (0.73 to 0.81) 
1.22 (1.77 to 1.88) 
1.67 (1.60 to 1.75) 
2.23 (2.12 to 2.34) 
2.75 (2.59 to 2.91) 
4.10 (3.90 to 4.32) 
Number of physical morbidities 
None 
One 
Two 
Three 
Four 
Five 
Six  
Seven or more 
 
635 (3.7) 
2,154 (12.5) 
2,916 (16.9) 
3,302 (19.1) 
2,947 (17.1) 
2,272 (13.1) 
1,479 (8.6) 
1,580 (9.1) 
 
800,019 (57.0) 
292,513 (20.8) 
147,369 (10.5) 
81,222 (5.8) 
43,876 (3.1) 
22,241 (1.6) 
10,261 (0.7) 
6,970 (0.5) 
 
0.90 (0.10 to 0.80)  
0.51 (0.49 to 0.54) 
0.84 (0.81 to 0.88) 
1.38 (1.32 to 1.44) 
1.97 (1.89 to 2.06) 
2.67 (2.54 to 2.81) 
3.40 (3.20 to 3.62) 
5.10 (4.79 to 5.43) 
Number of mental morbidities  
None 
One 
Two 
Three or more 
 
12,425 (71.9) 
3,487 (20.3) 
1,172 (6.8) 
201 (1.2) 
 
1,193,418 (84.9)  
161,011 (11.5) 
42,968 (3.1) 
7,074  (0.5) 
 
0.67 (0.65 to 0.70) 
1.41 (1.36 to 1.47) 
1.35 (1.27 to 1.43) 
1.39 (1.19 to 1.61) 
p=<0.001 unless stated  
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Figure 1. Prevalence and odds ratios for individual physical conditions (standardised by age, gender and deprivation score) 
 
 
Key; CHD=Coronary Heart Disease; CKD=Chronic Kidney Disease; PVD= Peripheral arterial disease; IBS=Irritable bowel syndrome; 
IBD=Inflammatory bowel disease . 
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Table 3 Prevalence and odds ratios for individual mental conditions (standardised by age, gender and deprivation score) 
 LVSD N (%) 
N=17,285  
Controls N (%) 
N=1,404,471  
Age, gender and 
deprivation 
standardised Odds Ratio 
(95% CI)  
Anxiety & stress related 1,906 (11.0) 53,41 (3.8) 1.83 (1.73 to 1.94)  
Alcohol problems 851 (4.9) 41,374 (3.0) 1.73 (1.62 to 1.86)  
Depression  2,810 (16.3) 140,587 (10.1) 1.52 (1.43 to 1.56)  
Learning Disability 57 (0.3) 4,950 (0.4) 1.50 (0.82 to 1.)  
Dementia  562 (3.3) 10,936 (0.8) 1.45 (1.26 to 1.67)  
Schizophrenia and bipolar disorder 199 (1.2) 12,237 (0.9) 1.19 (1.03 to 1.38) p=0.01 
Anorexia or bulimia 58 (0.3) 5,235 (0.4) 1.04 (0.87 to 1.39) p=0.34 
p=<0.001 unless stated
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Table 4 LVSD status and number of repeat medications  
Number of medications 
 
LVSD N (%) 
N=17,285  
Controls N (%) 
N=1,404,471  
Age, gender and deprivation 
standardised Odds Ratio 
(95% CI)  
Age, gender, deprivation and 
morbidity count 
standardised Odds Ratio 
(95% CI)  
 
None 
One or two 
Three or four 
Five or six 
Seven or eight 
Nine or ten 
Eleven or more 
1,322 (7.7%) 
1,226 (7.1%) 
2,251 (13.0%) 
3,527 (20.4%) 
3,470 (20.1%) 
2,433 (14.1%) 
3,056 (17.7%) 
864,813 (61.5%) 
242,533 (17.2%) 
126,833 (9.0%) 
80,170 (5.7%) 
46,595 (3.3%) 
24,322 (1.7%) 
21,827 (1.6%) 
0.16 (0.15 to 0.18) 
0.33 (0.31 to 0.35) 
0.64 (0.61 to 0.67) 
1.45 (1.39 to 1.51) 
2.39 (2.29 to 2.49) 
3.00 (2.85 to3.14) 
4.81 (4.60 to 5.04) 
0.46 (0.46 to 0.52) 
0.63 (0.59 to 0.67) 
0.76 (0.72 to 0.79) 
1.26 (1.21 to 1.32) 
1.56 (1.49 to 1.63) 
1.56 (1.48 to 1.64) 
1.81 (1.72 to 1.91) 
p=<0.001 unless stated
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Figure 2 Mean number of repeat prescriptions by number of morbidities in patients 
with LVSD and controls 
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